PBE - Invesco Dynamic Biotechnology & Genome ETFEquity - Sector Equity
The Invesco Dynamic Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex℠ Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of securities of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.
|Index History (%)|
|Dynamic Biotech & Genome Intellidex Index||-3.33||3.59||10.37||0.88||12.97||9.91|
|S&P Composite 1500 Biotechnology Index||-6.82||3.03||6.33||1.59||15.98||12.83|
|Fund History (%)|
|After Tax Held||-3.40||2.90||10.00||0.71||12.51||9.48|
|After Tax Sold||-2.01||1.72||7.82||0.60||10.55||8.09|
|Fund Market Price||-3.35||2.76||10.08||0.85||12.60||9.54|
|Index History (%)|
|Dynamic Biotech & Genome Intellidex Index||19.02||19.02||13.46||2.67||13.54||10.23|
|S&P Composite 1500 Biotechnology Index||16.98||16.98||9.62||4.03||17.36||13.46|
|Fund History (%)|
|After Tax Held||18.25||18.25||13.13||2.50||13.08||9.80|
|After Tax Sold||10.80||10.80||10.31||1.98||11.06||8.37|
|Fund Market Price||18.78||18.78||13.19||2.61||13.16||9.86|
Market returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times. Performance data quoted represents past performance, which is not a guarantee of future results. Investment returns and principal value will fluctuate, and shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than performance data quoted. After-tax returns reflect the highest federal income tax rate but exclude state and local taxes. Fund performance reflects applicable fee waivers, absent which, performance data quoted would have been lower. After Tax Held and After Tax Sold are based on NAV. Returns less than one year are cumulative.
Growth of $10,000
Data beginning 10 years prior to the ending date of 12/31/2019. Fund performance shown at NAV.
An investor cannot invest directly in an index. The results assume that no cash was added to or assets withdrawn from the Index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Market Cap & Style Allocations
as of 02/14/2020 Top Holdings | View All
Fund Holdings subject to change
|Ticker||Company||% of Fund|
|LLY||Eli Lilly & Co||5.83|
|BMY||Bristol-Myers Squibb Co||5.59|
|JNJ||Johnson & Johnson||5.29|
|MRK||Merck & Co Inc||4.58|
|ENDP||Endo International PLC||3.41|
Risk & Other Information
Typically, security classifications used in calculating allocation tables are as of the last trading day of the previous month.
There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The Fund's return may not match the return of the Underlying Index. The Fund is subject to certain other risks. Please see the current prospectus for more information regarding the risk associated with an investment in the Fund.
Investments focused in a particular industry, such as biotechnology and genome, are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments.
Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.
The Fund is non-diversified and may experience greater volatility than a more diversified investment.
The fund may engage in frequent trading of its portfolio securities in connection with the rebalancing or adjustment of the Underlying Index.
The S&P Composite 1500® Biotech (S&P Biotech) Index consists of all biotechnology stocks included in the S&P Composite 1500® Index.
The Global Industry Classification Standard was developed by and is the exclusive property and a service mark of MSCI, Inc. and Standard & Poor's.
ICE Data Indices, LLC, is used with permission. Dynamic Biotech & Genome IntellidexSM Index (“Index”) is a service/trade mark of ICE Data Indices, LLC or its affiliates and has been licensed for use by Invesco Capital Management LLC, in connection with the Invesco Dynamic Biotechnology & Genome ETF (the “Product”). Neither Invesco Capital Management LLC, Invesco Exchange-Traded Fund Trust nor the Product, as applicable, is sponsored, endorsed, sold or promoted by ICE Data Indices, LLC, its affiliates or its Third Party Suppliers (“ICE Data and its Suppliers”). ICE Data and its Suppliers make no representations or warranties regarding the advisability of investing in securities generally, in the Product particularly, the Trust or the ability of the Index to track general market performance. Past performance of an Index is not an indicator of or a guarantee of future results.
ICE DATA AND ITS SUPPLIERS DISCLAIM ANY AND ALL WARRANTIES AND REPRESENTATIONS, EXPRESS AND/OR IMPLIED, INCLUDING ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, INCLUDING THE INDICES, INDEX DATA AND ANY INFORMATION INCLUDED IN, RELATED TO, OR DERIVED THEREFROM (“INDEX DATA”). ICE DATA AND ITS SUPPLIERS SHALL NOT BE SUBJECT TO ANY DAMAGES OR LIABILITY WITH RESPECT TO THE ADEQUACY, ACCURACY, TIMELINESS OR COMPLETENESS OF THE INDICES AND THE INDEX DATA, WHICH ARE PROVIDED ON AN “AS IS” BASIS AND YOUR USE IS AT YOUR OWN RISK.
Beta is a measure of risk representing how a security is expected to respond to general market movements. Smart Beta represents an alternative and selection index based methodology that seeks to outperform a benchmark or reduce portfolio risk, or both. Smart beta funds may underperform cap-weighted benchmarks and increase portfolio risk.